Chemotherapy for ovarian cancer - a consensus statement on standard practice
1998

Chemotherapy for Ovarian Cancer: A Consensus Statement

Sample size: 1000 Editorial Evidence: high

Author Information

Author(s): M Adams, AH Calvert, J Carmichael, PI Clark, RE Coleman, HM Earl, CJ Gallagher, TS Ganesan, ME Gore, JD Graham, PG Harper, GC Jayson, SB Kaye, JA Ledermann, RJ Osborne, TJ Perren, CJ Poole, JA Radford, GJS Rustin, ML Slevin, JF Smyth, H Thomas, PM Wilkinson

Primary Institution: Royal Marsden Hospital

Conclusion

The combination of cisplatin and paclitaxel provides a significant survival advantage for ovarian cancer patients compared to standard platinum-based chemotherapy.

Supporting Evidence

  • Two large independent studies showed a significant survival advantage for the combination of cisplatin and paclitaxel.
  • The survival benefit from the combination treatment is approximately 1 year.
  • Previous studies indicated that carboplatin and cisplatin are equally effective in terms of long-term survival.
  • Current evidence supports the use of either cisplatin or carboplatin in combination with paclitaxel.

Takeaway

Doctors agree that using a mix of two specific drugs, cisplatin and paclitaxel, helps women with ovarian cancer live longer than using just one type of drug.

Methodology

The editorial summarizes findings from large randomized trials and meta-analyses regarding chemotherapy treatments for ovarian cancer.

Limitations

The editorial does not provide new data but summarizes existing studies and consensus opinions.

Participant Demographics

The studies referenced included over 1000 patients with ovarian cancer.

Statistical Information

P-Value

<0.000001

Confidence Interval

(0.56-0.77)

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication